Grant Award Details
Tissue Collection for Accelerating iPSC Research in Cardiovascular Diseases
- Recruit 680 patients with dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), and control cases for CIRM iPSC Repository.
Heart failure is a leading cause of morbidity and mortality in California and the Western world with a significant economic burden due to the disease. Over half of heart failure cases are due to dilated cardiomyopathy, a disorder of progressive ventricular dilation and decreased contractility. However, after ischemic cardiomyopathy, the majority of familial cases of dilated cardiomyopathy are unknown or "idiopathic", suggesting a polygenic etiology with a complex genetic-environmental interaction. Traditionally, studying this disorder has been impaired by inability to access cardiac tissue and the limitation of mouse models in recapitulating the disorder. Thus, we propose using human induced pluripotent stem cells (iPSCs) to study idiopathic familial dilated cardiomyopathy (IFDC). We propose collecting tissue from individuals identified with the disorder In summary, this proposal represents a unique
opportunity to improve our understanding of idiopathic familial dilated cardiomyopathy (which remains largely a mystery), identifying novel genetic causes (rendering many of these patients no longer “idiopathic), and proposing new therapeutic targets.
Heart failure is a leading cause of mortality and morbidity in California and Western world. Over half of heart failure causes are due to dilated cardiomyopathy, a disorder of progressive ventricular dilatation and decreased contractility. However, the mortality rate for heart failure has been stagnant over the past few years nationally and in California. Hence new knowledge and developments gained from this research can go a long way to ameliorating the burden caused by this disorder. Our goal here is to collect tissues from patients with heart failure so that induced pluripotent stem cells (iPSCs) can be generated to understand their disease mechanism.
Over the course of the past 3 years, we have collected blood samples from over 500 patients with heart failure without a clear genetic cause. We also shared de-identified clinical information about the patients who donated these samples. These samples will be used to make induced pluripotent stem cells, which are human cells that can divide into many other cell types such as heart, nerve or liver cells. These cells express the original genetic information of the person who originally donated the blood, in other words the beating heart cells created from this technology are very similar to the heart cells in the body of the original sample donor. This is a useful way of studying diseased heart cells and understanding how they differ from normal heart cells. This is especially useful in studying diseases that run in families but the genetic cause is unknown. The samples collected by our group will form a unique bio-bank of cells that have complete clinical information about the patients who donated them, which means that a scientists can study the heart cells in a dish knowing the clinical disease information about the cells. The bank of cells that have so far been created by this study will create a tremendous resource for scientists to study heart failure and develop new treatments for it.
Grant Application Details
- Tissue Collection for Accelerating iPSC Research in Cardiovascular Diseases
Heart failure is a very common and chronic condition defined by an inability of the heart to pump blood effectively. Over half of cases of heart failure are caused by a condition called dilated cardiomyopathy, which involves dilation of the heart cavity and weakening of the muscle. Importantly, many cases of this disease do not have a known cause and are called “idiopathic” (i.e., physicians do not know why). Over the past 2 decades, doctors and scientists started realizing the disease can cluster in families, leading them to think there is a genetic cause to the disease. This resulted in discovering multiple genes that cause this disease. Nonetheless, the majority of cases of dilated hearts that cluster in families do not have a known genetic cause. Now scientists can turn blood and skin cells into heart cells by genetically manipulating them and creating engineered stem cells called “induced pluripotent stem cells” or iPSCs. This approach enables the scientists to study what chemical or genetic changes are happening to cause the problem. Also because these cells behave similar to the cells in the heart, scientists can now test new medicines on these cells first before trying them in patients. Here we aim to collect tissue from 800 patients without a known cause for their dilated hearts (and 200 control individuals) to help accelerate our understanding of this debilitating disease and hopefully offer new and better treatments.
Statement of Benefit to California:
Heart failure is a significant health burden in California with rising hospitalization and death rates in the state. We have a very limited understanding of the disease and so far the existing treatments only slow down the disease and the changes that happen rather than target the root cause. By studying a subgroup of the dilated cardiomyopathy patients who have no identified cause, we can work on identifying genetic causes of the disease, some of the biology happening inside the heart cell, and provide new treatments that can prevent the disease from happening or progressing. Improving the outcome of this debilitating disease and providing new treatments will go a long way to helping a large group of Californians lead healthier and longer lives. There are estimates that the US economy loses $10 billion (not counting medical costs), because heart failure patients are unable to work. Hence new knowledge and developments gained from this research can go a long way to ameliorating that cost. Finally, heart failure is the most common chronic disease patients in California are hospitalized for. This research targets over half of those admissions. If this research is able to cut the hospitalization rate even by 1%, this would translate to millions of dollars in savings to the state. Continuing to invest in innovation will make our state a hotbed for the biotechnology industry, which in turn advances the state’s economic and educational status.
Source URL: https://www.cirm.ca.gov/our-progress/awards/tissue-collection-accelerating-ipsc-research-cardiovascular-diseases